These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19128200)

  • 1. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
    Heidbreder C
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.
    Heidbreder CA; Newman AH
    Ann N Y Acad Sci; 2010 Feb; 1187():4-34. PubMed ID: 20201845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.
    Heidbreder C
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):167-76. PubMed ID: 23104235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective dopamine D3 receptor antagonists: a review 2001-2005.
    Micheli F; Heidbreder C
    Recent Pat CNS Drug Discov; 2006 Nov; 1(3):271-88. PubMed ID: 18221209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Perspectives on Selective Dopamine D
    Newman AH; Xi ZX; Heidbreder C
    Curr Top Behav Neurosci; 2023; 60():157-201. PubMed ID: 35543868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dopamine D3 receptor, a quarter century later.
    Sokoloff P; Le Foll B
    Eur J Neurosci; 2017 Jan; 45(1):2-19. PubMed ID: 27600596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior.
    Andreoli M; Tessari M; Pilla M; Valerio E; Hagan JJ; Heidbreder CA
    Neuropsychopharmacology; 2003 Jul; 28(7):1272-80. PubMed ID: 12700694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D3 receptor antagonists: a patent review (2007 - 2012).
    Micheli F; Heidbreder C
    Expert Opin Ther Pat; 2013 Mar; 23(3):363-81. PubMed ID: 23282131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.
    Xi ZX; Gardner EL
    CNS Drug Rev; 2007; 13(2):240-59. PubMed ID: 17627675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings.
    Le Foll B; Collo G; Rabiner EA; Boileau I; Merlo Pich E; Sokoloff P
    Prog Brain Res; 2014; 211():255-75. PubMed ID: 24968784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats.
    Chen Y; Song R; Yang RF; Wu N; Li J
    Eur J Pharmacol; 2014 Nov; 743():126-32. PubMed ID: 25261038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.
    Heidbreder CA; Gardner EL; Xi ZX; Thanos PK; Mugnaini M; Hagan JJ; Ashby CR
    Brain Res Brain Res Rev; 2005 Jul; 49(1):77-105. PubMed ID: 15960988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of central neurotensin receptors reinstates cocaine seeking in the rat: modulation by a D1/D5, but not D2/D3, receptor antagonist.
    Lopak V; Erb S
    Psychopharmacology (Berl); 2005 Oct; 182(2):297-304. PubMed ID: 16010538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.
    Newman AH; Blaylock BL; Nader MA; Bergman J; Sibley DR; Skolnick P
    Biochem Pharmacol; 2012 Oct; 84(7):882-90. PubMed ID: 22781742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.
    Rothman RB; Glowa JR
    Mol Neurobiol; 1995; 11(1-3):1-19. PubMed ID: 8561954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat.
    Cervo L; Cocco A; Petrella C; Heidbreder CA
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):167-81. PubMed ID: 16426478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
    Keck TM; John WS; Czoty PW; Nader MA; Newman AH
    J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction.
    Filip M; Zaniewska M; Frankowska M; Wydra K; Fuxe K
    Curr Med Chem; 2012; 19(3):317-55. PubMed ID: 22335511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.
    Mason CW; Hassan HE; Kim KP; Cao J; Eddington ND; Newman AH; Voulalas PJ
    J Pharmacol Exp Ther; 2010 Jun; 333(3):854-64. PubMed ID: 20228156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dopamine D3 receptor and drug dependence: effects on reward or beyond?
    Le Foll B; Goldberg SR; Sokoloff P
    Neuropharmacology; 2005 Sep; 49(4):525-41. PubMed ID: 15963538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.